Navigation Links
Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies
Date:4/28/2009

OSLO, Norway, April 28 /PRNewswire/ -- Affitech AS, the human antibody therapeutics company, announced today that preclinical data on two fully human anti-PS (phosphatidylserine) antibodies were presented by its collaboration partner Peregrine Pharmaceuticals at the 100th Annual Meeting of the American Association for Cancer Research (AACR) 2009 held during April 18 - 22, 2009 in Denver, CO. The preclinical studies of PGN635 and PGN632 provided further confirmatory evidence that the anti-tumor effects observed with anti-PS antibodies reflect their immunomodulatory mechanism of action, including their ability to stimulate the immune system. Additionally, PGN635 demonstrated encouraging signs of efficacy in a preclinical model of prostate cancer. Both antibodies were isolated using Affitech's unique MBAS (Molecule Based Antibody Screening) method for selection and improvement of fully human antibodies from large libraries.

The researchers from Peregrine, Affitech and UT Southwestern Medical Center confirmed previous observations that in vitro, anti-PS antibodies stimulate the tumor microenvironment to recruit monocytes and other immune cells to the tumor with resulting anti-tumor effects, most likely via cell-mediated mechanisms such as antibody-dependent cell-mediated cytotoxicity (ADCC). Their data further defined the role of anti-PS antibodies in mediating tumor cell cytotoxicity and the tumor microenvironment, showing that the anti-PS antibody induced a sequential release of cytokines and beta-chemokines and stimulated enhanced macrophage recruitment to tumors. Furthermore, the researchers showed that in vitro, PGN635 induced antibody-dependent death of endothelial cells, the same cell type found in the tumor vasculature, a key target of anti-PS cancer therapy. The studies also demonstrated the anti-tumor potential of PGN635 in vitro and in a number of animal cancer models. Specifically, in a mouse model of prostate cancer, treatment with a mouse equivalent of PGN635 significantly retarded the growth of tumors by more than 90%.

In a separate study, researchers from UT Southwestern Medical Center (Peregrine's academic collaborators) and Affitech demonstrated in in vitro studies that immature dendritic cells cultured in the presence of PGN632 exhibited a significant increase in the production of inflammatory cytokines and chemokines. PGN632 also induced an increase in the expression of cell-surface molecules that are indicative of mature dendritic cells and that assist in antigen presentation functions, as well as in stimulating T-cell proliferation.

"These results demonstrate the efficiency and robustness of Affitech's range of antibody discovery platforms which include CBAS (Cell Based Antibody Screening) in addition to MBAS. They are being applied with increasing success to build proprietary oncology pipelines for both collaborators such as Peregrine and for ourselves," said Dr Martin Welschof, CEO of Affitech AS.

Commenting on the research progress of the antibodies and Peregrine's collaboration with Affitech, Steven King, President and CEO of Peregrine Pharmaceuticals said, "As leaders in the development of anti-PS antibodies for both oncology and anti-viral applications, we are delighted with these promising data for our fully human anti-PS antibodies from Affitech. They are the result of our well-established and highly productive collaboration and we look forward to continuing success in this and other projects."

For more information on Peregrine's anti-PS programs, visit http://www.peregrineinc.com


'/>"/>
SOURCE Affitech AS
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
2. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
3. Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity
4. Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrines Fully Human Anti-PS Antibody in Prostate Cancer Model
5. Human Genome Sciences Presents New Data Showing Anti-Tumor Activity And Safety Of Trail Receptor Antibodies In Combination With Chemotherapy
6. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
7. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
8. CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date
9. Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies
10. Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation
11. Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrines PS-Targeting Antibodies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... April 29, 2016 Glycotope GmbH, ... today announces the appointment of Dr. Alfredo Zurlo ... is an oncologist with many years clinical experience and ... industries. His last role was at Mologen AG where ... Executive Board. Previously Dr. Zurlo held various positions at ...
(Date:4/28/2016)... , April 28, 2016   Click ... Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest ... signed a definitive agreement to acquire Valley Campus ... Pharmacy ("TNH"), a leading specialty pharmacy that provides ... Nuys, California . In 2015, TNH generated ...
(Date:4/28/2016)... 2016 Research and Markets has ... Products Market 2016-2020" report to their offering. ... The global plastic surgery products market is expected ... period 2016-2020. , ,The growing adoption of laser in ... of the market. Lasers are used to treat a ...
Breaking Medicine Technology:
(Date:4/30/2016)... ... April 30, 2016 , ... ... inMotion3D Abstract users can distort and manipulate three-dimensional shapes with ease all within ... rows, ranks, point, lines, polygons, polygon texture animation, opacity texture animation, overall shape ...
(Date:4/30/2016)... ... April 30, 2016 , ... Saturday, April 30, marks World ... on public health. The World Veterinary Association (WVA) and the World Organization for ... continuing education with a One Health focus, which emphasizes how veterinarians pursue continuing ...
(Date:4/30/2016)... , ... April 30, 2016 , ... “Aging well is a challenge for all of us, but there are things ... Parul T. Kohli . “Research is showing more and more that there are simple, yet ... and disability as we age.” Top priorities Dr. Kohli’s recommends for her patients include;, ...
(Date:4/29/2016)... ... April 30, 2016 , ... Mercy College is expanding ... The following programs will be expanding due to high demand: Master of Business Administration ... will begin this summer. , School of Business Graduate Program Chair Dr. ...
(Date:4/29/2016)... Fl (PRWEB) , ... April 29, 2016 , ... ... recently notified by the Accreditation Council for Graduate Medical Education (ACGME) that it ... , This is the first accreditation of three residency programs that Memorial is ...
Breaking Medicine News(10 mins):